
CAREDX INC
CDNANASDAQTrading Snapshot
- Day Range
- $46.86 โ $47.86
- 52-Week Range
- $11.27 โ $49.76
- Volume
- $2.86B
- Avg Volume
- $2.16B
- Shares Outstanding
- 51.7M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $380M
- Last Q Revenue
- $132M
- P/E Ratio
- 21.9
- P/S Ratio
- 5.3x
- EPS (TTM)
- $2.16
- Dividend Yield
- 0.00%
Why Investors Own CDNA
- โHigh-growth profile โ revenue up +16.5% YoY with expanding US Equity exposure.
- โHealthy economics โ 37% gross margin and 9% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CAREDX INC
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
CareDx (NASDAQ:CDNA) Posts Accelerating Growth and Strengthening Fundamentals
CareDx stock aligns with Navellier's growth rules: accelerating earnings, rising estimates, margin expansion, high ROE. A momentum-oriented pick worth review.
BTIG Maintains Buy on CareDx, Raises Price Target to $60
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $45 to $60.

CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.

12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is at
HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $46 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral and maintains $46 price target.

CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsNina DekaJohn Hanna - President, CEO & DirectorKeith Kennedy -...